Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Health

220,000 people by 2028, about 6% of those eligible: MPs call the weight-loss jab plan 'unambitious'

Qurexa Editorial Team23 October 20266 min read 0 0
220,000 people by 2028, about 6% of those eligible: MPs call the weight-loss jab plan 'unambitious'

What happened

The House of Commons Health and Social Care Committee has published a report saying the NHS plan to offer the weight-loss injection tirzepatide, sold as Mounjaro, is moving far too slowly. The report came out on 22 October 2026 and is the second from the committee's inquiry into food and weight management. At the heart of it is one number. The current plan is for around 220,000 people in England to get Mounjaro free on prescription in 2028. The committee called that a "woefully small" figure. It works out at roughly 6% of the people who would qualify. The NHS has been working to a rollout spread over about 12 years, mainly because of cost. That timetable is under review. The committee wants the government to reassess the pace urgently, and says one way to do it is to make better use of digital providers, which already handle much of the process online. Layla Moran MP, who chairs the committee, said people "can spend their entire lives battling with their weight" and that those people are being repeatedly failed.

Why this matters

Two things are happening at once. The NHS is rationing a treatment carefully, and a very large private market has grown up beside it. More than a million people in the UK have already paid privately for weight-loss injections such as Mounjaro or Wegovy. The committee warned that this is creating a "two-tier system", where good access depends on what you can afford rather than how ill you are. There is a safety side to this as well. When people cannot get a licensed treatment through the NHS and cannot afford a private prescription, some turn to unlicensed products sold online. Those products are not checked, not traceable, and sometimes are not the medicine they claim to be. The committee called for a crackdown on that black market, a public awareness campaign about the dangers, and a review of how these products are advertised online. Andy Morling, the MHRA's deputy director of criminal enforcement, has put the limits of enforcement plainly: "we cannot arrest our way out of this." In other words, shutting down illegal sellers helps, but it does not remove the reason people go looking in the first place.

What the evidence actually says

It is worth separating the cost argument from the clinical one. On cost, the figures are genuinely large. The NHS has estimated that around 2.8 million patients in England would be eligible, and that if all of them came forward in the first year the bill would be about £15.2 billion over five years. That is the reason for the slow timetable, not reluctance. Against that, the committee points to the cost of obesity itself, which it puts at least £74.3 billion a year to the UK, with other estimates nearer £75 billion. More than two-thirds of the UK population live with overweight or obesity. On the clinical side, NICE recommended tirzepatide in June 2024 for adults with a body mass index of at least 35 who also have at least one weight-related health condition. Wegovy is available on the NHS only through specialist weight management services. The committee's bigger argument is about how obesity is treated as a category. It wants the government to publish a Modern Service Framework for obesity that recognises it as a "lifelong, relapsing and remitting condition that requires ongoing management", in the same way type 2 diabetes is handled, with clear standards for delivery and accountability. It also called for better access to diet and lifestyle courses and to weight-loss surgery, suggesting an initial target of around 13,000 bariatric procedures a year, roughly double the current number. Pharmacy bodies have said they are ready to take on more. Henry Gregg, chief executive of the National Pharmacy Association, said "community pharmacy is ready to support a wider rollout". Malcolm Harrison, chief executive of the Company Chemists' Association, argued pharmacies are well placed to extend the NHS's reach. The report also says pharmacies and other providers need secure access to relevant patient records, and should be able to record that a patient is taking a GLP-1 medicine. NHS England says it is looking at ways to speed up the rollout but is currently prioritising people with the most severe and complex needs.

Qurexa perspective

We work in pharmacy logistics, so the record-keeping point in this report is the one we would underline. If a patient is taking a GLP-1 medicine from a private provider and their GP does not know, that is a real safety gap. Anyone prescribing or dispensing for them afterwards is working with half the picture. The practical thing you can do is simple: tell your GP and your regular pharmacist what you are taking, even if you bought it privately. Nobody is going to tell you off. They just need to know. The other point we would make strongly is about buying online. If a seller does not ask you any health questions, does not need a prescription, or is offering a price far below everyone else, that is not a bargain. That is a warning sign.

Practical advice

**If you think you might be eligible on the NHS,** speak to your GP. Eligibility currently depends on your BMI and other health conditions, and services are prioritising people with the most complex needs. **If you are paying privately,** use a pharmacy or provider registered with the General Pharmaceutical Council, and expect to be asked detailed health questions. A proper consultation is a good sign, not an obstacle. **Never buy weight-loss injections from social media sellers, messaging apps or marketplaces.** Fake pens have been seized in the UK in large numbers. You cannot tell by looking. **Tell your GP and pharmacist.** Ask for it to be added to your record, so anyone treating you knows what else you are taking. **Do not stop other treatment on your own.** If a weight-loss medicine changes your appetite, your other medicines, including diabetes treatment, may need reviewing. That is a conversation, not a decision to make alone. **Remember medicines are only part of it.** The committee's own recommendations put diet and lifestyle support, and surgery where appropriate, alongside the injections rather than behind them.

What to know

MPs on the Health and Social Care Committee say the NHS plan to give around 220,000 people Mounjaro free by 2028, roughly 6% of those eligible, is unambitious, and they want the pace reassessed. They warn a two-tier system is emerging between those who can pay privately and those who cannot, and they want action on the illegal online market. They also want obesity treated as a long-term condition, with a Modern Service Framework, better access to lifestyle support and about 13,000 weight-loss operations a year. NHS England says it is looking at speeding things up while prioritising the most severe cases. Sources: Chemist+Druggist, "Weight loss management services must be 'overhauled', say MPs", 22 October 2026, https://www.chemistanddruggist.co.uk/news/weight-loss-management-services-must-be-overhauled-say-mps-VP3TSNTCPBGPTJXADCNJVF6NCY/; Pulse Today, "MPs demand weight management overhaul amid 'unambitious' Mounjaro rollout", 22 October 2026, https://www.pulsetoday.co.uk/news/clinical-areas/gastroenterology-obesity/mps-demand-weight-management-overhaul-amid-unambitious-mounjaro-rollout; BBC News (syndicated via Yahoo News), Nick Triggle, "Give more people weight loss jabs on the NHS, say MPs", 22 October 2026, https://www.yahoo.com/news/us/articles/more-people-weight-loss-jabs-230609454.html. This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.

#obesity#weight loss drugs#Mounjaro#NHS#pharmacy#health policy

Related articles